Biomarker Chip for Osteoarthritis

骨关节炎生物标记芯片

• 批准号: 6551356
• 负责人: Stephen Francis Kingsmore
• 金额: $ 10万
• 依托单位: MOLECULAR STAGING, INC.
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-09-11 至 2004-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6551356
• 关键词: antibody; biomarker; cartilage; clinical research; cytokine; diagnosis design /evaluation; human tissue; microarray technology; musculoskeletal disorder diagnosis; osteoarthritis; physiologic bone resorption; synovial fluid

DESCRIPTION (provided by applicant): Osteoarthritis (OA) is the most prevalent musculo-skeletal disease in the older adult population, characterized by chronic pain and life long disability. The current 'gold standard' for diagnosis of OA is radiology, but radiological changes occur relatively late in the disease after the bone tissue changes responsible for the pain and disability have already taken place. A diagnostic test that uses biomarkers of OA for early detection would be useful in early diagnosis and treatment, ameliorating symptoms and potentially lessening disability. The general goal of this project is to produce a microarray for detecting proteins in serum that are biomarkers of OA including cytokines and products of cartilage & bone catabolism In order to achieve sufficient sensitivity, this microarray will utilize a novel proprietary technology, rolling circle amplification, for signal amplification. The RCA-enabled microarray will offer the benefits of multiplexing (measuring approximately 100 analytes simultaneously), reduced sample volume (only 15 ul/assay), high-throughput, and exceptional sensitivity (ca. 10 pg/mI). Initial studies will be done with serum from patients with OA and appropriate controls using our current cytokine chip. We also will identify other reagents as potentially useful biomarkers for OA with the aim of designing an OA chip.

描述（由申请人提供）：骨关节炎（OA）是老年人群中最普遍的肌肉骨骼疾病，其特征是慢性疼痛和长期残疾。目前用于诊断OA的“黄金标准”是放射学，但是放射学变化在疾病中相对较晚发生，因为骨骼组织变化导致了疼痛和残疾的发生。使用OA生物标志物进行早期检测的诊断测试将有助于早期诊断和治疗，改善症状并可能减轻残疾。该项目的一般目标是生产一个微阵列，用于检测血清中的蛋白质，该蛋白质是OA的生物标志物，包括细胞因子和软骨和骨骼分解代谢的产物，以实现足够的敏感性，这种微阵列将利用新型的专有技术，用于滚动圆圈，以进行信号扩增。启用RCA的微阵列将提供多路复用的好处（同时测量了大约100个分析物），样本体积减少（只有15 ul/sassay），高通量和异常灵敏度（10 pg/mi）。最初的研究将使用我们当前的细胞因子芯片的OA患者的血清和适当的对照。我们还将确定其他试剂是OA的潜在有用的生物标志物，目的是设计OA芯片。